AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06499961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital version of Holistic Healthy Life Education
Description: Participants need to attend a two-day workshop related to (1) health risk appraisal and self-care; (2) exercise, fitness and self-acupressure; (3) emotion and stress management; (4) the whole food plant-based (WFPB) diet; and (5) meditation and mindfulness practices, led by a multi-disciplinary team. Before the intervention commences, they will take pre-blood test and further receive the e2HLE with Hera Leto for three months. During the intervention, participants will attend (1) nine weekly workshops pertaining to WFPB diet, exercise, fitness and self-acupressure, and meditation and mindfulness and followed by weekly tele-counselling sessions; (2) three process evaluation practice sharing sessions in the format of focus group, making up a total of twelve sessions. The process evaluation practice sharing sessions will be audio-recorded; (3) mutual support networking platform will be held between case managers and participants within Hera Leto system.
Study NCT06499961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: usual care first, then switch to receive the intervention
Study NCT05490472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-2485 (Aurora A inhibitor)
Description: Administered orally
Study NCT05465746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM)
Description: Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
Study NCT05465746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Three-dimensional transthoracic echocardiography
Description: Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
Study NCT06343389 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinine
Description: to detect patients with Acute kidney injury
Study NCT05147740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
Study NCT06226467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurobehavioral Affective Control Training
Description: The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (\~30 minutes) practicing two computer-based adaptive training tasks targeting affective control.
Study NCT06226467 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurobehavioral Affective Control Training
Description: The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (\~30 minutes) practicing two computer-based adaptive training tasks targeting affective control.
Study NCT04974047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously as specified in the treatment arm.
Study NCT05671757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Study NCT05671757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Study NCT05671757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Study NCT06492408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.
Study NCT06409858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Twice-weekly mat Pilates class for 8 weeks, either in person or online (depending on participant availability)
Study NCT05061992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28.
Study NCT05568758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic lymphatic pump technique
Description: The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
Study NCT05568758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises (stretching and strenghtening )
Description: stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises
Study NCT06432140 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VGN-R09b injection
Description: Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
Study NCT05229510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/mL Virazole Inhalant Product
Description: 50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study NCT05229510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/mL Virazole Inhalant Product
Description: 100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study NCT06180694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Description: In the research, reminiscence therapies will be carried out once a week for 8 weeks, in sessions of approximately 45 minutes.
Study NCT05822544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-6740 Oral Solution
Description: Oral solution of TLC-6740
Study NCT05822544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-to-match
Study NCT05822544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-6740 Tablet
Description: Tablet formulation of TLC-6740
Study NCT05822544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Metabolizing Enzyme
Description: Oral dose of omeprazole, voriconazole, or itraconazole
Study NCT05265052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 (50 mg)(Phase IIa)
Description: 1 tablet of 3D1002 per oral dose
Study NCT05265052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 (100 mg)(Phase IIa)
Description: 2 tablets of 3D1002 per oral dose
Study NCT05265052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 (150 mg)(Phase IIa)
Description: 3 tablets of 3D1002 per oral dose
Study NCT05265052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 monotherapy (Phase IIb)
Description: 3D1002 is administered at recommended dose with mimic OxyContin tablets.
Study NCT05265052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyContin monotherapy (Phase IIb)
Description: OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
Study NCT05265052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 + OxyContin (Phase IIb)
Description: 3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
Study NCT06166004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance Training device with VR
Study NCT06166004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-Specific Rehabilitation Program
Description: Person-Specific Rehabilitation Program
Study NCT06481813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sampling (2*8mL Tubes)
Description: Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)
Study NCT06481813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PBMC Sampling (1*8mL Tubes)
Description: Patients will be sampled from 1 x 8 mL PBMC
Study NCT06481813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paxgene Sampling
Description: Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube
Study NCT06481813 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extended biopsies of tumor lesions
Description: Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology.~The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³.~For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³.~In the case of a complex biopsy, no additional sampling related to the research will be performed.
Study NCT05229510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study NCT06115603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabigerol
Description: 1 mL of 80mg Cannabigerol once during experimental session
Study NCT06115603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of placebo once during experimental session
Study NCT06166004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Person-Specific Rehabilitation Program
Description: Person-Specific Rehabilitation Program
Study NCT06273540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STP7 (mavoglurant) or Placebo
Description: STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.
Study NCT06273540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP7 (mavoglurant) or Placebo
Description: STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.
Study NCT05530538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainWeighve App
Description: 46 total adolescents (14-18 years old) with %BMIp95 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll two successive groups of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually).
Study NCT05081271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous booster
Description: Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
Study NCT05081271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heterologous booster
Description: Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
Study NCT05420337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group ıntramuscular
Description: Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
Study NCT05420337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group TAP
Description: Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
Study NCT06029218 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proteus ONE one daily beam
Description: A single daily beam is used, doubling the dose delivered for this treatment incidence.
Study NCT06029218 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proteus ONE two daily beam
Description: two daily beams are used, in accordance with the initial treatment plan and the patient's standard of care
Study NCT05852990 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Glutamine plus L. reuteri
Description: Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
Study NCT05838612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: Participants will complete a 7-day passive heat acclimation protocol consisting of immersion in warm water (\~40°C) for 1 hour over 7 consecutive days.
Study NCT04908163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet-based nutritional education intervention
Description: The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
Study NCT04908163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet-based culinary intervention
Description: The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
Study NCT05759221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with airway biopsy
Description: Forceps biopsy of peripheral airways under direct endoscopic visualisation.
Study NCT05475223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: End Tidal Carbon Monoxide Value
Description: A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
Study NCT05357287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREVENA incision management system
Description: We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
Study NCT05659758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head up positioning during preoxygenation
Description: patients will be preoxygenated in head up position
Study NCT05659758 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Head up positioning during preoxygenation
Description: patients will be preoxygenated in head up position
Study NCT05612776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
Study NCT05612776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV
Description: The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
Study NCT05128929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hymecromone (H01)
Description: 800 mg oral H01 two times a day (total dose: 1600 mg/day).
Study NCT05128929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet placebo (inactive ingredients) two times a day.
Study NCT05573386 — intervention group
Intervention type: DRUG
Intervention: Filgrastim
Description: human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
Study NCT05573386 — intervention group
Intervention type: DRUG
Intervention: Pegfilgrastim
Description: long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
Study NCT06267430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kleuter Extra training program
Description: The intervention was described in the included arm/group explanation.
Study NCT06726889 — intervention group
Intervention type: BEHAVIORAL
Intervention: Decision Support System (DSS)
Description: DSS will be used to deliver educational material through a web-page (in Italian language) accessible through a link